27 May 2011

Female hormonal contraceptives market forecast to hit US$7.2 in 2014 says new report

But, post 2014, the market value will fall as generics come to market

The market for female hormonal contraceptives is estimated to grow by 5% from $6.9bn in 2011 to $7.2bn by 2014, says a new report from URCH Publishing. However, after 2014, the market value will decline by over 19% to $5.5bn by 2018 as cheaper generics offset premium brands and innovative products.

The Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 says that market leaders for female contraception include Bayer with annual revenues of $3bn, followed by Teva at $1.2bn, and Merck & Co. with $1bn in annual sales. High-revenue products include Bayer’s Yasmin/Yaz/Yasminelle franchise; Mirena, Merck & Co.’s NuvaRing; and Teva’s Ocella and Sprintec product lines, which collectively account for US$3.5bn in annual revenues.

Drivers of growth for the hormonal contraception sector will be novel transdermal and intravaginal products that offer greater efficacy, lower dosing, and improved and longer control over menstruation.

The report notes that “double-digit growth will be based on the introduction of sophisticated next-generation products along with prospects for male contraception, but this has yet to prove successful in long-term clinical trials.” Currently, there are over 40 pipeline candidates for female and male contraception.

The 67 page report analyses current product markets, research and development themes, and company activities within the field. The report evaluates sales trends and pharmacological innovation, and provides a detailed account of the newly approved and pipeline prospects that are anticipated to expand the market substantially over the next decade. Updates on novel drug development for male contraception and male infertility are detailed in addition to the commercial opportunities based on unmet needs.

The report provides insights for product extension and reformulation, sales forecasts to 2018, and allows for assessments of the impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also presented showing products from preclinical to premarket authorization phases of development. Therapy area forecasting to 2018 enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modeling.

Back to press releases >>